Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial

Next Previous
X
Search
Trial Profile

European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 05 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Baricitinib (Primary) ; Bemcentinib (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Therapeutic Use
  • Acronyms Bari-SolidAct; EU-SolidAct; SolidAct

    • Most Recent Events

    • 02 Feb 2023 Status changed from recruiting to discontinued.
    • 27 Sep 2022 According to BerGenBio media release, the first patient has been included in a study of BerGenBios oral, highly selective AXL inhibitor, bemcentinib, as part of this EU-SolidAct trial in hospitalized COVID-19 patients
    • 26 Jan 2022 According to BerGenBio media release, EU-SolidAct has established clinical sites in 15 countries. The trial is sponsored by Oslo University Hospital, Norway in collaboration with the Institut National de la Sante Et de la Recherche Medicale (Inserm), France and the not-for-profit intergovernmental organization European Clinical Research Infrastructure Network (ECRIN). The EU-SolidAct trial is part of EU-RESPONSE.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top